Immupharma Share Discussion Threads

[elrico] 08/4/2018 13:47

Good article in today's TimeshTTps://twitter.com/LEMMINGINVESTOR/status/982962247508135937?s=19

[fuji99] 08/4/2018 13:39

For tripple ham info, I will buy more tomorrow even at 200p as within a year or as early as next few weeks, it could tripple in value but not in hamhamham.

[squiresquire] 08/4/2018 13:37

Very interesting Times article today. They agree with the many other grounded estimates i have read that the share price could, if good news were delivered, double from the £1.70 area..

That is completely in line with my own investing/gambling play with IMM as its high risk and from £1.72 possibly could double. So target of £3.40.....or 86p

This is hardly the huge multi bagging £ 500 per share that so many on this thread have been repeating ad infinitum so they can trade in and out.

Just Double, on as high a risk as this, isnt much of an attraction, so i dont think this article will do much good to the share price other than a rapid rise, then fall as the stupid buy in having misunderstood the article.

There are far far far more solid companies, with none of the really big risk associated with the previous AIM Pharma test failures that will also be doubling in the near future.

Sylviane Muller pulling out of the conference Monday isnt good. Why would she not go at this crucial stage? the reason of bad transport hardly cuts it at all.

Now its clearly written by a good journalist that the reward isnt anywhere at all near the totally stupid prices posted on this board again and again and again.

Now i feel certain we will get a huge sell off at some point this week before the results are released.

[fuji99] 08/4/2018 13:18

Now that the radars of the likes of GSK and Sanofi are on IMM, the only outcome is a takeover. 5 or 25 pounds depending on Lupuzor performance. So with or without hamham or anybody else throwing repetitive doubts in the hope their shorts won't be stuck tomorrow, I will hold this, one in a lifetime, share.

[money maker1] 08/4/2018 12:33

Results out this week, possibly tomorrow, followed by a takeover:

miavoce
7 Apr '18 - 13:22 - 23783 of 23798

I wouldn't normally do this as it isn't fair to subscribers, but to avoid the misunderstandings and mis-statements that this thread is prone to here are the key points from the SCSW item:-

- SCSW met with the company in the last month
- Simbec Orion has spent the last few weeks cleaning up the data and ensuring it has been accurately input into the database
- Database lock and unblinding will be on 6 April
- Analysis of data will be done and top line results available in the following week (i.e this coming week)
- After the results IMM will be anywhere from 30p to 500p+ depending on the outcome
- Hopes for the latter given earlier trial data was good and the safety profile excellent
- IMM has appointed a European M&A specialist
- A bid at a multiple of the price is inevitable on success.

[witsend1] 08/4/2018 12:14

Why does Ham get so much stick? Reality check for me - although it is looking very hopeful

[ny boy] 08/4/2018 11:30

Just noticed the former co-founder & Chairman of IMM Richard L. Warr, who passed away in July 2015, the family still hold 3.5M shares (2.89%) A sizeable holding.

[hamhamham1] 08/4/2018 11:29

Opodio. I do own some shares, deal with it. I am just not up to my neck in them like some here. GLA.

[city chappy] 08/4/2018 11:24

Immupharma looking good for a quick $15 to $20 billion takeover on positive results this week.

Edit - Just read the £179 to £358 share price valuation. Looks achievable on those figures, especially as Lupuzor P140 could treat many indications.

[rnsday] 08/4/2018 11:12

@ham they can also read through the heap of your posts and make their own mind up on what your true agenda is here :)

[hamhamham1] 08/4/2018 11:09

You just cannot handle the fact that I own a few at this point. Money I can write off if p3 is bad. Or buy more at 100% premium at per the article if p3 is good

[goodbloke1] 08/4/2018 11:07

Well it's obvious you want in much cheaper given you sold lol and then you will ramp if you got your buy in price

[hamhamham1] 08/4/2018 11:03

Well all The Times article readers can thumb though this board and see the cult of ramping here which vaciferously attacks any non-ramping posts. They cam make their own minds up on the posters here.

[hamhamham1] 08/4/2018 10:51

Stay classy eh?

[money maker1] 08/4/2018 10:35

Results out this week, possibly tomorrow, followed by a takeover:

miavoce
7 Apr '18 - 13:22 - 23783 of 23798

I wouldn't normally do this as it isn't fair to subscribers, but to avoid the misunderstandings and mis-statements that this thread is prone to here are the key points from the SCSW item:-

- SCSW met with the company in the last month
- Simbec Orion has spent the last few weeks cleaning up the data and ensuring it has been accurately input into the database
- Database lock and unblinding will be on 6 April
- Analysis of data will be done and top line results available in the following week (i.e this coming week)
- After the results IMM will be anywhere from 30p to 500p+ depending on the outcome
- Hopes for the latter given earlier trial data was good and the safety profile excellent
- IMM has appointed a European M&A specialist
- A bid at a multiple of the price is inevitable on success.

[hottingup] 08/4/2018 10:32

hamhamham1 #23885, I see you have again only posted the cautionary sentences instead of the full article, which is overwhelmingly positive about Immupharma:


This promising small-cap stock could be a millionaire maker in 2018
Paul Summers
26/12/2017



The suggestion that a single stock could lead some investors to become millionaires next year may sound fanciful but I think this is quite possible if events work out for small-cap drug discovery and development firm ImmuPharma (LSE: IMM). Let me explain.

Blockbuster potential

Over the last three months, shares in the AIM-listed company have climbed more than 200% in value as anticipation grows over the outcome of a Phase III clinical trial for Lupuzor — its 100%-owned potential treatment for Lupus.

Approximately five million people are believed to suffer from the chronic and potentially life-threatening autoimmune disease that can be a notoriously difficult to treat. In the last 50 years, only one therapy — GlaxoSmithKline‘s Benlysta — has been approved for use, despite its questionable efficacy and serious side-effects. In 2015, the drug achieved sales of over $400m. By 2020, this figure is expected to rise to $1bn.

Positively, data from Lupozor’s Phase IIb trial indicated that ImmuPharma’s treatment — which modulates rather than blocks the immune system — was both effective and safe. Moreover, the effectiveness of Lupuzor increased even after the three-month trial’s conclusion. Investors will be hoping that the 52-week, randomised and double-blinded study currently in progress (involving patients in the US, Europe and Mauritius) yields similar results.

In its most recent update on 21 December, the company revealed that all 200 participants had now received the full 12-month dosage and that the “robust safety record” shown in earlier trials continues to be seen. According to Chairman Tim McCarthy, the company looks forward “with continued confidence” to reporting on top-line results in Q1 of next year.

In the event of a positive outcome, ImmuPharma will then seek to exploit its Fast Track designation and push for approval from the Food and Drug Administration (FDA). Once received, the company would then be free to seek out a global licensing deal for taking Lupuzor to market or — perhaps more likely — consider takeover bids by deep-pocketed pharmaceutical giants at a price befitting its blockbuster potential. Given the suggestion that it could be used in the treatment of other diseases, the price could easily be in the billions of pounds. Right now, ImmuPharma’s market cap is a little over £200m.

Tempted? If so, it’s vital to consider the flip side of this investment.

Despite the encouraging outcomes of previous trials, the possibility of the drug failing to impress still remains. Plenty of highly promising treatments have disappointed at the last hurdle, resulting in significant capital losses for investors. Unless you’re willing to embrace this level of risk, Immupharma shouldn’t even make it on to your watchlist, let alone into your portfolio.

That’s why — as a holder of its stock — only a small proportion of my capital is invested in the company. This money can be lost. I might grumble and curse but — thanks to a degree of diversification — I won’t lose my shirt.

That said, if — and it remains a sizeable ‘if‘ — Lupuzor proves effective (or at least more efficacious than Benlysta), I’m confident that ImmuPharma could generate huge wealth for investors in a very short time period.

No investment is devoid of risk but only you can decide whether this is one worth taking.